Exit-site infection in continuous ambulatory peritoneal dialysis: a review.
Although the ability of CAPD to successfully treat end-stage renal disease is now well established, exit-site infection (ESI) remains a serious cause of morbidity. The objective of this article is to review recent advancements relating to ESI pathogenesis and its reduction. Current definitions of ESI are reviewed, as are comparative studies of etiology. Emphasis is placed on the literature identifying Staphylococcus aureus as the primary cause of ESI in CAPD. The article reviews reported rates of ESI and discusses reasons for variations of this complication's reported frequency. The selection of catheters available in CAPD are discussed, as are studies demonstrating the threat of S. aureus to catheter survival. The pathogenesis of exit-site infection related to S. aureus nasal carriage in CAPD is reviewed in light of recent findings indicating the pre-CAPD nasal carrier as the patient at risk for subsequent ESI. Postoperative and long-term care of the catheter patient are reviewed for various literature protocols. Treatment recommendations for choice of agents are discussed. Future research should include a better understanding of the morphology of the CAPD catheter exit-site in humans and the healing process. ESI epidemiological studies should be encouraged in tandem with well-designed, controlled studies on the value of prophylactic treatment.
Luzar
M A
MA
Baxter R&D Europe, Nivelles, Belgium.
D006801:Humans; D007239:Infections / Q000453:epidemiology / Q000209:etiology* / Q000382:microbiology / Q000628:therapy; D010531:Peritoneal Dialysis, Continuous Ambulatory / Q000009:adverse effects*